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SUMMARY 
• The novel virus removal membrane BMMand the com- 
mercially available filter 
PLANOVAR
 based on this system provide 
results both reproducible and predictable for virus removal 
based on a sieving mechanism. The BMMshows good remov- 
ability of most viruses, including human immunodeficiency 
virus, hepatitis B and C and other microorganisms. In addi- 
tion, immune complexes can be removed efficiently with a good 
protein permeability. Although BMMhas already been shown 
to be effective in the field of drug manufacture, the combina- 
tion of virus removal using BMM with virus inactivation of- 
fers opportunities for the wider clinical application of BMM, 
including blood transfusion. 
INTRODUCTION 
• Recently appearing infections such as human immuno- 
deficiency virus (HIV), the etiologic agent of acquired immu- 
nodeficiency syndrome (AIDS), hepatitis C virus (HCV) and 
agent of the bovine spongiform encephalophaty (BSE) have 
given rise to new epidemics and generated the social demands 
to develop strategies against these infections. 
On the other hand, progress in biotechnology has accelerated 
the development of novel biodrugs. In order to protect patients 
from infections caused by the injection of the biodrugs contami- 
nated by microorganisms, guidelines have been completed in 
many countries such as the USA, European Union member 
states and Japan (1-3).  
With this advancement, it has also become necessary to develop 
a new technology for reducing and/or concentrating microor- 
ganisms arbitrarily. The virus removal membrane, named 
BMM, has been demonstrated to remove particles based mainly 
on their size. The BMM is fabricated from cuprammonium re- 
generated cellulose and shaped into the form of a hollow fi- 
ber. This membrane has two specific characteristics of repro- 
ducibility and predictability in virus removal. These two char- 
acteristics are prerequisite conditions for validation of virus 
removal in the biodrug purification process (4). 
Then this membrane is employed to decrease exogenous par- 
ticles, such as microorganisms and immune complexes from 
drugs or the body fluid of patients reduction of the particles can 
be assured. About sixty years ago, viruses were regarded as "lil- 
trable" microbes (5). Novel technology to remove particles se- 
lectively without damage or loss of valuable bioactive sub- 
stances, such as antibodies or antigen proteins, may play an 
important role in the strategy against viruses. In this review, 
recent topics relating to the virus removal membrane and its 
application will be discussed. 
  
  
 Selected abbreviations 
AIDS - acquired immunodeficiency syndrome 
BSE - bovine spongiform encephalophaty 
CJD - Creutzfeldt-Jakob's disease 
HBV - hepatitis B virus 
HCV - hepatitis C virus 
HIV - human immunodeficiency virus 
JEV - Japanese encephalitis virus 
MULV - murine leukemia virus 
points are yet to be clarified, we believe that this will be an in- 
teresting challenge in the application of our validation mem- 
brane. 
AIDS VIRUS REMOVABILITY 
• The size of HIV-1 is approx. 100 nni, which allows the 
virus to be removed easily with the validation membrane. Fig. 1 
shows the dependence of the viras logarithmic rejection coef- 
ficient <!> defined by equation 1 on the mean pore size 2rf. The 
solution employed was fresh frozen plasma (FFP) and HIV cul- 
ture supernatant and dead end filtration was performed under 
a constant transmembrane pressure (AP) of 200 mmHg (7). 
 
ADVANTAGE OF VIRUS REMOVAL COMPARED 
WITH VIRUS IMAGINATION 
• The main objective of drug administration against vi- 
rus infections is to reduce the infectivity of viruses in a pa- 
tient by inactivating the target viruses and/or by inhibiting the 
growth or generation of progeny viruses through biochemical 
reaction with the drugs. The side effects of the drugs may arise 
from injection of the exogenous bioactive substance and from 
the immune complexes of degraded viruses which have been 
degenerated by the inactivation. 
On the other hand, viras removal decreases the concentration 
of the virus resulting in viral infectivity diminution. The side 
effects caused by the removal procedure can be minimized 
through the employment of optimized conditions related to the 
absence of any additional substance. The only unsolved prob- 
lem has been the credibility of the procedure. The validation 
membrane overcomes this problem completely. , ; 
WHAT CAN BE EXPECTED IN THE BIOMEDICAL 
FIELD WHEN A VALIDATION MEMBRANE IS 
EMPLOYED? 
• Expectations of a validation membrane can be divided 
into two categories: prevention and treatment of virus infec- 
tions. The former expectation may be achieved by removing the 
virus from the drag injection solution (especially with bio- 
drugs) during purification in the manufacturing process. This 
expectation can be extended to the removal of immune com- 
plexes in addition to the viras from human plasma without loss 
of antibody proteins. The latter expectation is based on our 
strategy of reducing the viras titer in the blood of affected in- 
dividuals using this membrane. In HIV-infected patients, ag- 
gressive viral replication seems to occur even before the devel- 
opment of full-blown AIDS and this viras replication may play 
a very important role in the pathogenesis of HI V-1. In this case, 
some beneficial effect can be expected from reduction of the 
extent of viremia by the membrane filter. Although several 
Ф=log 10 (N0/Nf) 
where NQ and Nf are the infectivities of viruses in the original 
solution and its filtrate, respectively. Here, the arrow indicates 
that the viras concentration in the filtrate is less than the de- 
tectable level of 3.4 PFU/ml. The filtrates obtained through fil- 
tration with BMM ranging between 10 nm and 105 nm in mean 
pore size show no infectious particles. Decrease in viras infec- 
tivity was due to reduction of the viras concentration, but not 
to the inactivation resulting from the filtration. 
Fig.2 demonstrates transmission electron micrographs of the 
ultrathin section of the BMM50 after filtration of the culture 
supernatant of HIV-1 (6). The virions are distributed within 
the region ranging from the inner surface to a site 5 \im in from 
the inner wall surface if the hollow fiber indicating that the 
virions have been entrapped by the sieving mechanism and 
that milty-step filtration was achieved within the thickness of 
the hollow fiber wall. The frequency distribution of the viri- 
ons caught in BMM has been represented empirically by the 
linear relationship between their number and this relationship 
has been confirmed by the theoretical approach (8). When 
extrapolated to the outer surface, a <& value of BMM50 of more 
than twenty was obtained (7). This extrapolated value was also 
consistent with the value obtained by extrapolation of the lin- 
ear relationship between and the mean size of viras 2v (Fig.3) 
(9). This figure shows the dependence of O on 2v for the vari- 
ous virions, which were confirmed to be molecularly dispersed 
without forming aggregates. Fig.3 indicates that knowledge of 
thevirion size allows the removability of the viras in question 
by the BMM to be predicted. This predictability of viras re- 
moval is one of the conditions that are mandatory for a vali- 
dation membrane (4). 
Table 1 shows example of permeability of the antigen of P24 
for HIV-1 (6). All antigens composing an HIV virion whose 
molecular weight is less than 10
5
 can pass through the BMM, 
moreover, antibodies such as IgG and IgM and/or monoclonal 
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Figure 1. Dependence of logarithmic rejection coefficient 0 ofHIVon mean pore size 2rffor BMM under filtration condi- 
dions. Dead-end, i. e. perpendicular, filtration under constant transmembrane pressure AP of 200 mmffg (a). Dead-end fil- 
tration under the constant filtration rate ofL/mm-.min (b). Tangential (parallel) filtration oj AP=200 mmHg and the shear 
rate of 2000 sec'
1
 at the membrane surface (c). The symbols ofCS and FFP (a) indicate that the solutions dispersing HIV 
are the culture supernatant and the melt of fresh frozen plasma, respectively. The arrows on the data points indicate that 
the concentration of HIV in a filtrate is less than the detectable level. From Ref7. 
  
the mean pore size is more than 15 nm as is shown in the lat- 
ter section. 
When a BMM with a mean pore size of less than 100 nm is 
employed in the manufacturing process of biodrugs or in the 
preparation of human plasma, HIV infection caused by trans- 
fusion can be prevented. On the other hand, as suggested pre- 
viously, it may be possible for the BMM to be used for thera- 
peutic purposes in AIDS patients by inclusion of a BMM fil- 
tration process in extracorporeal circulation for plasma perfu- 
siori and by the injection of immunoglobulin prepared from 
pooled plasma of HIV carriers (8), i.e. as immunotherapy (10). 
This extracorporeal treatment may be effective based on the 
premise that the ratio between the concentration of the anti- 
body and that of the viruses plays an important role in the ac- 
tual manifestation of the disease. 
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Figure 2. Transmission electron micrographs ofBMMSO after the filtration of the supernatant of culture medium contain- 
ing HIV. Cross-section view with the remaining HIV virions caught in the BALM. The white region corresponds to the source 
material ofBMM, cellulose, and the black spots located at near the lumen correspond to HIV virions (a). An enlarged 
micrograph (b). Many mature HIV particles are localized in the narrow space restricted to an area of approximately 5 mm 
in depth from the luminal surface (a). High magnification of HIV virions caught by BMM (c). I.S. - inner surface ofBMM, 
O.S. - outer surface of BMM. From Ref 6. .......... .. 
  
Gene therapy has been developed recently using various viruses 
as vectors and this has led to a need for new technology for virus 
concentration. The virus removal filter was developed to meet 
this requirement. More specifically, when the PLANOVA
R
 fil- 
ter is employed for virus concentration, concentrated viruses 
can be obtained easily without significant loss of activity. An 
ecotropic murine leukemia virus (MULV) and HIV were con- 
centrated 10 to 30 fold from 500-1000 ml of culture superna- 
tant using PLANOVA
R
 with the filtration area of 0.03 m
2
 un- 
der the total live virus recovery rate of approx. 50 % (12). 
PLANOVA
R
 has been manufactured under more stringent 
quality control, such as the integrity test for each filter, than 
in the case of BMM. 
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" Fractation by ultracentrifugation was done as described in 
the text. 
 Filtration procedure with BMM is described in the text. 
 The concentration ofp24 infiltrandwas 183 ng/ml. The limit 
of detection of this method is lOOpg/ml. 
" Loss =A- ( B  + C) From Ref6. 
REMOVABILITY OF JAPANESE ENCEPHALITIS VIRUS, 
HEPATITIS B VIRUS, HEPATITIS C VIRUS AND OTHER 
VIRUSES 
• Japanese encephalitis virus (JEV) (13), hepatitis B vi- 
rus (HBV)(11, 14,15)andHCV(4,19) are similar in size and 
range between 35 and 43 nm. Although HCV size has not yet 
been completely determined, we can evaluate the size from the 
<& values of the BMM using the mean pore size of 35 nm (16- 
When BMM with a mean pore size of 3 5 nm (BMM3 5) is used, 
the infectivity of these viruses can be reduced to over the O 
value of four. Fig.4 (11) shows the mean pore size dependence 
of the O value for the Dane particle of HB V. The S-module 
and the M-module indicate that the filters are composed of a 
single hollow fiber and a multitude of hollow fibers, respec- 
tively. The numbers in parentheses indicate the effective fil- 
tration area in cm
2
. In this figure the <D value decreases with 
increasing effective filtration area and this tendency is not 
unexpected from the theoretical viewpoint. The validation 
membrane should not exhibit this tendency and should show 
  
 
Figure 3. Dependence of the virus logarithmic rejection coefficient 0 on virion size 2v for BMM50. The viruses employed 
are present inamonodispersedstate. Abbreviations: polio -polio virus, JEV-Japanese encephalitis virus, HIV-1 - human 
immunodeficiency virus-1, VSV - vesicular stomatitis virus, HSV-1 - herpes simplex virus-1. 
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Figure 4. Virus logarithmic rejection coefficient <t> of hepatitis B virus for a small module (S-module) and a medium mod- 
ule (A>i-module). The numbers in parentheses indicate filtration area in cm
2
. The broken line stands for the extrapolated 
value. 0 - 0  value for the M-module whose bubble point is more than 1 aim. © - 0 value for the M-module -whose bubble 
point more than 10 atrn. Arrows indicate that 0 value is more than that indicated by the arrow. From Ref 11. 
 
Figure 5. Electron micrographs of cross section ofBMMSO after filtration of Dane particles.  The inner (a) and outer (c) 
parts of the membrane. The entire cross-sectional view of the membrane (b). 
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Figure 6. Dependence of 0 of Japanese encephalitis 
virus (JEV) on mean pore size ofBMM. 
a constant value independent of the effective filtration area. 
This prerequisite can be achieved through the novel validation 
test method that we have proposed (20). 
The electron microphotographs of Dane particles entrapped in 
a pore of the BMM are shown in Fig.5 (21). The Dane par- 
ticles are packed like the eggs of a frog indicating that they have 
been caught through the plugging and trapping mechanism 
(21). The antigens of HBV such as HBs, HBe and HBc can pass 
easily through the BMM having a mean pore size larger than 
35 nm. 
The removability of JEV for the various BMM is summarized 
in Fig. 6. The empirical relation expressed by equation 2 was 
obtained between <b and 2rf (in nm). 
(2) Ф =(215/2rr)-l.l 
This equation is consistent with that derived from the theoreti- 
cal approach (8). The JEV virion was employed as the stan- 
dard virion to validate the BMM filter. When the filtration con- 
dition is kept constant, then the following empirical equation 
is derived. The reliability of this equation has been confirmed 
from the theoretical approach too. 
(3) Ф = Cl(2v/2rf)d - C2 
where Cl and C2 are constants independent of virion size 2v, 
mean pore size 2rf and membrane thickness d. Equation 3 is 
applicable to most viruses and/or particles in an isolated mono- 
dispersed state (9). Fig.7 represents particle size dependence 
of O value for four kinds of BMM: BMM15 (whose mean pore 
size is 15 run), BMM35 (35 nm),BMM40 (40 nm) andBMM75 
(75 nm) (22) The proteins of immunoglobulin G (IgG) can 
almost completely pass through BMM15, BMM35, and 
BMM40 indicating that most antibodies can pass through 
BMM under conditions excluding the contaminating viruses. 
In the case of HC V, because of the lack of a susceptible cell 
line to propagate the virus, a polymerase chain reaction (PCR) 
as the assay method was employed (17). Although this method 
was very sensitive in terms of HCV detection, the existence of 
a part of the RNA of HCV does not necessarily mean the pres- 
ence of an infectious virion. Next, an in vivo infection assay 
using chimpanzees in order to evaluate the concentration of 
HCV infectious particles was performend (17). Table 2 sum- 
marizes the results of the chimpanzee test for the HCV removal 
experiment, indicating that BMM35 can remove the infectious 
virions of HCV under the level of a 4 fold logarithmic reduc- 
tion. 
This level is consistent with that derived from the RNA removal 
data evaluated by the PCR method (16). Some pharmaceutical 
manufacturers have been employing BMM35 practically in 
their purification process based on their original data of HCV 
removal using BMM35 and their products have been approved 
by the Japanese government (23, 24). 
Microorganisms other than viruses, such as mycoplasma (25), 
the agent causing Creutzfeldt-Jakob's disease (CJD) (26), bac- 
teriophage (25) and bacteria, can also be removed using a se- 
ries of BMM filters with various pore size. In the first case, the 
mycoplasma deforms into a slender shape under the shear stress 
caused by the fluid stream resulting in a smaller cross sectional 
diameter than that of the usual shape under a static state. The 
CJD agent has not been observed clearly, but is named prion 
protein. The removability of this agent by BMM35 indicates 
that the causative agent of CJD forms an aggregate that is more 
than 40 nm in size (23, 26). In the case of bacteriophage, re- 
movability is higher than expected from its size and shape 
because of the formation of aggregates under normal condi- 
tions. Table 3 summarizes the O values of various microor- 
ganisms for five BMM with a different mean pore size. 
In the actual use of the BMM with a procured kidney to mini- 
mize HCV infection, not only the removability of HCV, but also 
the filtration capacity and filtration rate must be higher than 
the levels under actual operational conditions. When BMM35 
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Table 2. Results of chimpanzee test through injection offlltrand and filtrate 
 
+ poisitive, - negative; injection volume was 1 ml for each chipmanzee. 
*filtrand of the albumin solution containing hepatitis C virus having the CID   value oflO^/ml before filtration. 
**filtrand with CIDX of 10
3
/ml before filtration. From Rel18. 
 
Figure 7. Particle size dependence of 0for various viruses for BMM15 (a), BMM35 (b), BMM40 (c) and BMM75 (d) 
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Table 3. Logarithmic rejection coefficients of microbes for various BMM with different mean pore size 
 
was placed in series with the preservation apparatus, high levels 
of HCV removal from the perfusion solution and an adequate 
speed of filtration were achieved (27). 
As for the prion protein, the spread of BSE in cattle in Europe 
has posed a serious problem in the field of biotechnology. The 
BSE has potential for infection of humans since most of its 
biological characteristics are similar to those of CJD, which 
infects humans. Since bovine plasma has been an essential 
component of culture medium and may continue to play a vital 
role in biothechnology, validation of the purification process in 
the manufacture of a biodrug will be essential to protect from 
this infection (28). We have established a novel integrity test 
system for the validation membrane filter PLANOVA
R
 (20,29, 
30). It has led to a drastic increase in reliability of the quanti- 
tative level of virus removability. 
REMOVAL AND PERMEATION OF GENE DNA 
• Government regulations demand the removal of DNA 
molecules from biodrugs. According to the recommendations 
of the Food and Drug Administration of the USA, the content 
of residual DNA in a biodrug should be less than 100 pg/dose 
 
(1-3). These recommendations are based on the strategy to in- 
crease the safety of the biodrugs. In contrast, good separation 
of DNA from the virus is utilized in the purification of DNA. 
Technology for the separation and purification of DNA may 
be applied in gene therapy in the future. 
Fig. 8 shows the molecular weight dependence on permeabil- 
ity of DNA without the coexistence of proteins for the case of 
BMM35 and BMM15. 
 (4)    Ф=C/C 
where C f and C0 are the particle concentration in a filtrate and 
a feed solution, respectively. The permeability decreases lin- 
early with increased in molecular weights (MW). The MW50 
is defined as the MW at permeability of 50 %. MW values for 




, respectively (31). 
When DNA density in an aqueous solution pdis assumed to be 
1.7 g/ml, the corresponding volume Vd of the molecules with 
MW of 10
s








, respectively, using the following equation; 
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Figure 8. Molecular weight (MW) dependence on permeability <pofDNAforPLANOVA33 and PLANOVA15. The concen- 
tration of the proteins coexisting in the solution can be neglected. 
  
(5) Vd = MW/Na.pd     
where Na is Avogadro's number. If the DNA molecule with 
the above Vd assumes a spherical shape, then the size of both 





, respectively. These sizes are far beyond the mean 
pore size of the BMM. Consequently, the DNA molecule may 
easily deform into a yarn-like shape when the shear stress acts 
on the molecule in the pore. This speculation is confirmed 
through electronmicroscopic observation of the BMM after 
filtration of a solution containing DNA molecules. Fig.9 shows 
a cross-sectional view of a BMM hollow fiber (31, 32). The 
yarn-like-shaped DNA molecules can be observed at the inside 
of the membrane wall. When the permeability of DNA mol- 
ecules is controlled based on their deformability by shear stress 
generated in a pore, the DNA molecules can be purified and/ 
or separated easily based on their MW. When protein molecules 
coexist, permeability of the DNA molecule diminishes drasti- 
cally (33). 
 
In the production of proteins by the use of biotechnology, DNA 
molecules change with the reaction time (34, 35). Conse- 
quently, with PLANOVA", the removability of DNA produced 
during the bioreaction changes with the reaction time. The 
recovery rate of proteins can be kept at a high level during the 
entire reaction time (35). 
  
REMOVABILITY OF IMMUNE COMPLEXES AND PERMEABILITY 
OF PROTEINS INCLUDING MONOCLONAL ANTIBODY 
• Rheumatic factors in human plasma can be removed 
through a BMM with a mean pore size of less than 30 nm (36), 
indicating that most immune complexes have a large particle 
size of more than 20 nm, which corresponds to the size of IgM. 
Fig. 10 summarizes the dependence on the permeability of pro- 
teins in a solution having a concentration of less than 1% of 
their MW. When MW value increases the permeability of the 
protein decreases linearly as is the case of DNA molecules. The 
MW30 for BMM35 is 4xl0
7
 and is about one fiftieth of that of 
  






Figure 9. Cross-sectional view of BMM after filtration of a solution containing DNA. The yarn-like shaped DNA molecules 
can be obsen'ed on the inside of the membrane wall. The DNA molecules are stretches within the BMM wall due to the 
shear stress originating from the filtrate flow in a pore. 
  
the DNA molecule. We can speculate from comparison with 
the case of DNA molecules that a series of globulins having 
an inherent molecular shape with a bulky configuration can not 
be deformed by shear stress into a yarn-like shape, a tendency 
that is the same as that of viruses (37). 
The dependence of permeability of proteins on their MW for 
the BMM series with various mean pore sizes indicates that 
 
when a BMM with an appropriate mean pore size is employd 
can selectively be segregated harmful immune complexes with- 
out loss of valiable protein. Compared with plasma exchange 
for the removal of immune complexes from the human body, 
plasma perfusion with the BMM causes only minimal side 
effects due to the antigens transfused, such as viruses. 
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Figure 10. Dependence of permeabilitv of a protein on its molecular weight (MW) for BMAI10, BMM20, BMM50, 
PLANOVA15, and PMNOl''A35. Broken line - BALM series, fall line - PI.ANOVA series. 
  
COMBINATION OF VIRUS REMOVAL USING BMM 
AND INACTIVATION 
• The employment of virus inactivation treatment in ad- 
dition to virus removal explains the range of applications of 
the virus removal filter to include use in protection from virus 
infections. Problems in the actual application of BMM arise 
when the target virus is small since the permeability and/or 
recovery rate of effective proteins for human health decreases 
with a decrease in the mean pore size of the BMM for virus 
removal. This problem can be overcome by taking aggregates 
of the viruses by the respective antibodies and/or by combin- 
ing virus removal with virus inactivation treatment. The former 
solution seems to be possible in the case of parvo virus and of 
the causative agent of CJD (26). The latter solution can be car- 
ried out easily and is already utilized. The total degree of de- 
crease in virus infectivityby the process of virus removal and 
virus inactivation is nearly equal to the summation of that of 
each treatment when virus removal is conducted after virus 
inactivation and more than the summation in the case of the 
reverse order of these treatments (38). The removal of com- 
ponents that obstruct the inactivation of viruses accelerates the 
treatment. 
It is noteworthy that there is an optimum combination of virus 
removal and virus inactivation processes including their se- 
quence. Examples include heat-treatment after filtration using 
BMM35 whose mean pore size is 35 nm (38) and ultraviolet 
treatment after filtration using BMM35 (39). 
CONCLUSION 
• A validation membrane such as the BMM for virus re- 
moval allows predictability of this process. Its mechanism is 
based on a sieving effect. Consequently, this membrane can 
remove not only the virus, but also particles such as immune 
complexes, low density lipoproteins and others generated in the 
body fluid. The content of particles in human plasma tends to 
increase with the age of the donor indicating that the plasma 
composition can be adjusted to that of children by filtration 
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using BMM. Although application to the manufacture of un- 
contaminated "pure" drags has been implemented, the actual 
clinical application of BMM requires further investigation. 
The mechanism of particle removal (for example, the reduc- 
tion of the population of virions in a body) is different from 
that after the injection of drags. Accordingly, we can also ex- 
pect useful effects when particle removal and drag adminis- 
tration are combined. This is also the subject of a forthcoming 
study. 
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